Florence Hugues

Dr. Florence Hugues

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2023 in Animal Reproduction Science
Verified
Journal Article
Closed access
MGMiguel A. Gutiérrez-Reinoso
Miguel A. Gutiérrez-Reinoso
CACesar J. Arreseigor
Cesar J. Arreseigor
BDBrian Driedger
Brian Driedger
OCOscar Ignacio Cabezas
Oscar Ignacio Cabezas
FHFlorence Hugues
Florence Hugues
Manuel Garcia-HerrerosManuel Garcia-Herreros
Manuel Garcia-Herreros

Verified
Journal Article
Open access
PDF file
VAVerónica Avello
Verónica Avello
SSSantiago Alberto Salazar
Santiago Alberto Salazar
EHEddy Ernesto González Horta
Eddy Ernesto González Horta
PMPaula Canpos Martínez
Paula Canpos Martínez
Viana Manrique SuárezViana Manrique Suárez
Viana Manrique Suárez
RMRaquel Montesino
Raquel Montesino
Multivalent live-attenuated or inactivated vaccines are often used to control the bovine viral diarrhea disease (BVD). Still, they retain inherent disadvantages and do not provide the expected protection. This study developed a new vaccine prototype, including the external segment of the E2 viral protein from five different subgenotypes selected after a massive screening. The E2 proteins of every subgenotype (1aE2, 1bE2, 1cE2, 1dE2, and 1eE2) were produced in mammalian cells and purified by IMAC. An equimolar mixture of E2 proteins formulated in an oil-in-water adjuvant made up the vaccine candidate, inducing a high humoral response at 50, 100, and 150 µg doses in sheep. A similar immune response was observed in bovines at 50 µg. The cellular response showed a significant increase in the transcript levels of relevant Th1 cytokines, while those corresponding to the Th2 cytokine IL-4 and the negative control were similar. High levels of neutralizing antibodies against the subgenotype BVDV1a demonstrated the effectiveness of our vaccine candidate, similar to that observed in the sera of animals vaccinated with the commercial vaccine. These results suggest that our vaccine prototype could become an effective recombinant vaccine against the BVD.

22 October 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TRThelvia Isabel Ramos
Thelvia Isabel Ramos
CVCarlos Villacís
Carlos Villacís
FSFelipe Sandoval
Felipe Sandoval
Sarah Martin-SolanoSarah Martin-Solano
Sarah Martin-Solano
Viana Manrique SuárezViana Manrique Suárez
Viana Manrique Suárez
JTJorge Roberto Toledo
Jorge Roberto Toledo
Background: Interferons (IFNs) are cytokines involved in the immune response with a synergistic regulatory effect on the immune response. They are therapeutics for various viral and proliferative conditions, with proven safety and efficacy. Their clinical application is challenging due to the molecules’ size, degradation, and pharmacokinetics. We are working on new drug delivery systems that provide adequate therapeutic concentrations for these cytokines and prolong their half-life in the circulation, such as nanoformulations. Methods: Through nanoencapsulation using electrospray technology and biocompatible and biodegradable polymers, we are developing a controlled release system based on nanoparticles for viral infections of the respiratory tract. Results: We developed a controlled release system for viral respiratory tract infections. A prototype nanoparticle with a core was created, which hydrolyzed the polyvinylpyrrolidone (PVP) shell , releasing the active ingredients interferon-alpha (IFN-α) and interferon-gamma (IFN-γ). The chitosan (QS) core degraded slowly, with a controlled release of IFN-α. The primary and rapid effect of the interferon combination ensured an antiviral and immunoregulatory response from day one, induced by IFN-α and enhanced by IFN-γ. The multilayer design demonstrated an optimal toxicity profile. Conclusions: This formulation is an inhaled dry powder intended for the non-invasive intranasal route. The product does not require a cold chain and has the potential for self-administration in the face of emerging viral infections. This novel drug has applications in multiple infectious, oncological, and autoimmune conditions, and further development is proposed for its therapeutic potential. This prototype would ensure greater bioavailability, controlled release, fewer adverse effects, and robust biological action through the simultaneous action of both molecules.

1 October 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
TRThelvia Isabel Ramos
Thelvia Isabel Ramos
CVCarlos Villacís
Carlos Villacís
FSFelipe Sandoval
Felipe Sandoval
Sarah Martin-SolanoSarah Martin-Solano
Sarah Martin-Solano
Viana Manrique SuárezViana Manrique Suárez
Viana Manrique Suárez
JTJorge Roberto Toledo
Jorge Roberto Toledo
Interferons (IFNs) are cytokines involved in the immune response with synergistic regulatory action. They are therapeutics for various viral and proliferative conditions, with proven safety and efficacy. Their clinical application presents difficulties due to the molecules' size, degradation, and pharmacokinetics. We developed a controlled release system for viral respiratory tract infections. A core-shell nanoparticle was prototyped, which hydrolyzed the shell (polyvinylpyrrolidone), releasing the active ingredients IFN-α and IFN-γ. The core (chitosan) degraded slowly, with a controlled release of IFN-α. The primary and rapid effect of the combination of interferons ensured an antiviral and immunoregulatory response from day one, induced by IFN-α and enhanced by IFN-γ. The multilayer design demonstrated an optimal toxicity profile. This formulation is an inhaled dry powder targeted for the non-invasive intranasal route. This prototype would ensure greater bioavailability, controlled release, fewer adverse effects, and robust biological action thanks to the simultaneous impact of both molecules.

2 October 2024 in Tropical Animal Health and Production
Verified
Journal Article
Closed access
PDF file
Viana Manrique SuárezViana Manrique Suárez
Viana Manrique Suárez
NGNicolás Gutiérrez
Nicolás Gutiérrez
AHAngela Hidalgo-Gajardo
Angela Hidalgo-Gajardo
EHEddy Ernesto González Horta
Eddy Ernesto González Horta
FHFlorence Hugues
Florence Hugues
JTJorge Roberto Toledo
Jorge Roberto Toledo

14 July 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
ELEmilio Lamazares
Emilio Lamazares
AVAleikar Vásquez-Suárez
Aleikar Vásquez-Suárez
KGKelly Gancino
Kelly Gancino
FSFelipe Sandoval
Felipe Sandoval
JYJaviera Yáñez-Torres
Javiera Yáñez-Torres
JTJorge Roberto Toledo
Jorge Roberto Toledo
Early embryonic loss is a major cause of reproductive inefficiency in cattle, primarily due to premature luteolysis. Interferon tau (IFN-τ), secreted by the trophoblast, plays a critical role in maternal recognition of pregnancy by maintaining corpus luteum function. However, its practical application has been limited by its rapid degradation and short half-life in vivo. Here, we developed a novel formulation of recombinant bovine IFN-τ, combining chitosan-based microencapsulation with starch–chitosan hydrogel delivery, enabling sustained intrauterine release. This dual-delivery strategy offers a significant improvement over conventional IFN-τ administration methods that rely on repeated intrauterine infusions of soluble protein. The rbIFN-τ was expressed in Pichia pastoris, purified to 90.1% homogeneity, and structurally validated via homology modeling and molecular docking, confirming its interaction with type I interferon receptors. The encapsulated formulation retained antiviral activity, stimulated transcription of interferon-stimulated genes (PKR, OAS1, OAS2), and showed sustained release in vitro for up to 26 days. In vivo evaluation demonstrated safety and biological efficacy, with treated cattle showing inhibited luteolysis, sustained serum progesterone levels, and preserved corpus luteum integrity. This formulation represents a promising biotechnological approach to improve reproductive efficiency through a long-acting, species-specific IFN-τ delivery system.